Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia

• Status: Completed
• Trial end date: 2005-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Individuals with schizophrenia are three times as likely to smoke cigarettes as individuals without schizophrenia. While a great deal of research has been focused on smoking cessation programs for healthy individuals, little attention has been directed towards developing an effective smoking cessation treatment for schizophrenics. This project will evaluate the effects of 0, 21 and 42 mg transdermal nicotine on smoking, urge to smoke, and nicotine withdrawal symptoms after 5 hrs abstinence in smokers with schizophrenia and heavy-smoking non-psychiatric control smokers.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Institute on Drug Abuse (NIDA)
• Treatments: Nicotine

Criteria

Inclusion Criteria:

• Smokes between 20 and 50 cigarettes per day

• Diagnosis of schizophrenia or schizoaffective disorder

Exclusion Criteria:

• If enrolled in the control group, must not be diagnosed with a psychiatric disorder

• Currently dependent on alcohol or any drug (other than nicotine)

• Currently trying to quit smoking

• Currently taking bupropion, desipramine, clonidine, buspirone, or doxepin

• History of liver disease

• History of heart attacks or chest pain

• Allergic to adhesives

• Pregnant or breastfeeding